title: Diabetes mellitus type 2 is associated with higher levels of myeloperoxidase.
abstract: BACKGROUND
  Diabetes mellitus type 2 is linked to augmented endothelial dysfunction and accelerated atherosclerosis. Myeloperoxidase plays an important role in the initiation, progression, and the complications of atherosclerosis. We investigated whether myeloperoxidase levels are increased in diabetic patients.
  
  
  METHODS
  We compared baseline plasma myeloperoxidase levels in diabetic and nondiabetic patients with mild, stable anginal complaints (Canadian Cardiovascular Society I-II/IV) and performed multivariate linear regression analyses to adjust for possible confounding factors.
  
  
  RESULTS
  A total of 440 patients were recruited from the outpatient clinic of cardiology, 268 patients with and 172 without diabetes mellitus type 2. Levels of myeloperoxidase were significantly higher in diabetic patients (median, 141 pM; interquartile range, 115-171 pM) than in nondiabetic patients (median, 126 pM; interquartile range, 105-167 pM) (P=0.01). Diabetes mellitus type 2, age in years, current smoking status, presence of hypercholesterolemia, and use of calcium antagonists and ACE inhibitors were associated with logarithmically transformed myeloperoxidase levels. Of these variables, diabetes mellitus type 2 (beta 0.096, SE 0.038, P=0.01); age (beta 0.01, SE 0.002, P<0.001), and current smoking (beta 0.166, SE 0.05, P=0.001) remained independently associated with myeloperoxidase levels in multivariate analysis. The linear regression coefficient of diabetes mellitus type 2 in relation to myeloperoxidase was 0.092 in univariate linear regression and 0.078 after adjusting for age, current smoking, and use of ACE inhibitors and calcium antagonists.
  
  
  CONCLUSIONS
  Diabetes mellitus type 2 is associated with mildly increased levels of myeloperoxidase, independent of other clinical variables. This association may contribute to the accelerated progression of atherosclerosis in diabetics.
authors.affiliation: Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands. j.j.wiersma@amc.uva.nl
authors.forename: Jacobijne J
authors.initials: JJ
authors.lastname: Wiersma
authors.forename: Marijn C
authors.initials: MC
authors.lastname: Meuwese
authors.forename: Joram N I
authors.initials: JN
authors.lastname: van Miert
authors.forename: Arnoud
authors.initials: A
authors.lastname: Kastelein
authors.forename: Jan G P
authors.initials: JG
authors.lastname: Tijssen
authors.forename: Jan J
authors.initials: JJ
authors.lastname: Piek
authors.forename: Mieke D
authors.initials: MD
authors.lastname: Trip
mesh_terms: D000368:Aged; D000787:Angina Pectoris / Q000150:complications; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000201:enzymology*; D005260:Female; D006801:Humans; D008297:Male; D009195:Peroxidase / Q000378:metabolism*
chemical_list: D009195:Peroxidase